First-line metformin use for DM up; sulfonylurea use down

First-line metformin use for DM up; sulfonylurea use down

(HealthDay)—Among patients with type 2 diabetes initiating antidiabetes drugs (ADDs), first-line use of metformin has increased since 2005, while sulfonylureas have remained the most popular second-line agent, according to a study published online Nov. 6 in Diabetes Care.

Olga Montvida, from Queensland University of Technology in Australia, and colleagues used data from the U.S. Centricity Electronic Medical Records to identify 1,023,340 patients with type 2 (aged 18 to 80 years) who initiated any ADD and 357,482 patients who initiated second-line ADD after first-line .

The researchers found that between 2005 and 2016, first-line use of metformin increased from 60 to 77 percent, while first-line use of sulfonylureas decreased from 20 percent to 8 percent. Over a mean 3.4 years of follow-up, post-metformin, 48 percent initiated a second ADD at a mean HbA1c of 8.4 percent. Although sulfonylurea usage as a second-line treatment decreased (60 to 46 percent), it remained the most popular second ADD choice, while use increased for insulin (7 to 17 percent) and dipeptidyl peptidase-4 inhibitors (0.4 to 21 percent).

"Most initiate second-line therapy at elevated HbA1c levels, with highly heterogeneous clinical characteristics across ADD classes," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.


Explore further

Diabetes treatment failure may actually be nonadherence

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: Diabetes Care

Copyright © 2017 HealthDay. All rights reserved.

Citation: First-line metformin use for DM up; sulfonylurea use down (2017, November 19) retrieved 16 September 2019 from https://medicalxpress.com/news/2017-11-first-line-metformin-dm-sulfonylurea.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more